International journal of clinical practice
-
Int. J. Clin. Pract. · Dec 2017
Review Meta AnalysisGlobal improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis.
Global rating scale measures are useful for assessing the clinical relevance of patient change. Cariprazine, a dopamine D3 and D2 receptor partial agonist, is FDA-approved for the adult treatment of acute manic/mixed episodes of bipolar I disorder and schizophrenia. Post hoc evaluations of Clinical Global Impressions-Severity (CGI-S) scores from the cariprazine pivotal trials in both indications were conducted. ⋯ Post hoc analyses showed that more cariprazine- than placebo-treated patients with bipolar mania or schizophrenia had statistically significant and clinically meaningful CGI-S improvement.